PDF
ePub
Citation
Print
Abstract
Recent researches have suggested approaches to HIV immunization that might result in at least a partially effective vaccine against infection with HIV-1. In particular, advances in our understanding of animal models, the vaccine-elicited celluar immunity and neutralizing antibody provide rational strategies for the development of this vaccine. Some advanced-phase clinical trials of HIV vaccine are ongoing. Although the creation of an effective HIV-1 vaccine remains an enormous challenge, the continuing progress in these areas provides a reason to be optimistic about our ultimate ability to control the spread of AIDS.
Figures and Tables
References
1. Borkow G. Mouse models for HIV-1 infection. IUBMB Life. 2005. 57:819–823.
2. Sharp PM, Shaw GM, Hahn BH. Simian immunodeficiency virus infection of chimpanzees. J Virol. 2005. 79:3891–3902.
3. Letvin NL, King NW. Immunologic and pathologic manifestations of the infection of rhesus monkeys with simian immunodeficiency virus of macaques. J Acquir Immune Defic Sydr. 1990. 3:1023–1040.
4. Reimann KA, Li JT, Vaazey R, Halloran M, Park IW, Karlsson GB, Sodroski J, Letvin NL. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J Virol. 1996. 70:6922–6928.
5. Le Rouzic E, Benichou S. The Vpr protein from HIV-1: distinct roles along the viral life cycle. Retrovirology. 2005. 2:11.
6. Joag SV. Primate models of AIDS. Microbes Infect. 2000. 2:223–229.
7. Plotkin SA. Immunologic correlates of protection induced by vaccinatin. Pediatr Infect Dis J. 2001. 20:63–75.
8. Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, Hayes D, Louder MK, Brown CR, Sapan CV, Frankel SS, Lu Y, Robb ML, Katinger H, Birx DL. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol. 1999. 73:4009–4018.
9. Conley AJ, Kessler JA II, Boots LJ, McKenna PM, Schleif WA, Emini EA, Mark GE III, Katinger H, Cobb EK, Lunceford SM, Rouse SR, Murthy KK. The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate. J Virol. 1996. 70:6751–6758.
10. Emini EA, Schleif WA, Nunberg JH, Conley AJ, Eda Y, Tokiyoshi S, Putney SD, Matsushita S, Cobb KE, Jett CM, Eichberg JW, Murthy KK. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature. 1992. 355:728–730.
11. Gilbert PB, Chiu YL, Allen M, Lawrence DN, Chapdu C, Israel H, Holman D, Keefer MC, Wolff M, Frey SE. NIAID HIV Vaccine Trial Network. Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored phase I and II clinical trials. Vaccine. 2003. 21:2933–2947.
12. de Bruyn G, Rossini AJ, Chiu YL, Holman D, Elizaga ML, Frey SE, Burke D, Evans TG, Corey L, Keefer MC. Safety profile of recombinant canarypox HIV vaccines. Vaccine. 2004. 22:704–713.
13. Gupta K, Hudgens M, Corey L, McElrath MJ, Weinhold K, Montefiori DC, Gorse GJ, Frey SE, Keefer MC, Evans TG, Dolin R, Schwartz DH, Harro C, Graham B, Sperarman PW, Mulligan M, Goepfert P. AIDS Vaccine Evaluation Group. Safety and immunogenicity of a high-titered canarypox vac-cine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group protocol 022A. J Acquir Immune Defic Syndr. 2002. 29:254–261.
14. Duerr A, Wasserheit JN, Corey L. HIV vaccines: new frontiers in vaccine development. Clin Infect Dis. 2006. 43:500–511.
15. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, Kilby JM, Saag MS, Komarova NL, Nowak MA, Hahn BH, Kwong PD, Shaw GM. Antibody neutralization and escape by HIV-1. Nature. 2003. 422:307–312.
16. Rowland-Jones S, Sutton J, Ariyoshi K, Dong T, Gotch F, McAdam S, Whitby D, Sabally S, Gallimore A, Corrah T, Takiguchi M, Schultz T, McMichael A, Whittle H. HIV-specific cytotoxic T-cell in HIV-exposed but uninfected Gambian woman. Nat Med. 1995. 1:59–64.
17. Rowland-Jones S, Dong T, Fowke KR, Kimani J, Krausa P, Newell H, Blanchard T, Ariyoshi K, Oyugi J, Ngugi E, Bwayo J, MacDonald KS, McMichael AJ, Plummer FA. Cytotoxic T cell response to multiple conserved HIV epitopes in HIV-1 resistant prostitutes in Nairobi. J Clin Invest. 1998. 102:1758–1765.
18. Kannagi M, Chalifoux LV, Lord CI, Letvin NL. Suppression of simian immunodeficiency virus replication in vitro by CD8+ lymphocytes. J Immunol. 1988. 140:2237–2242.
19. Goulder PJ, Phillips RE, Cobert RA, McAdam S, Oqq G, Nowak MA, Giangrande P, Luzzi G, Morgan B, Edwards A, McMichael AJ, Rowland-Jones S. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med. 1997. 3:212–217.
20. Plotkin SA, Orenstein WA, editors. Vaccine. 2004. 4th ed. Pennsylvania: Elsevier;1219–1258.
21. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, Hu D, Tappero JW, Coopanya K. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis. 2006. 194:1661–1671.
22. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF. The rgp120 HIV Vaccine Study Group. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis. 2005. 191:654–665.
23. Goepfert PA, Horton H, McElrath MJ, Gurunathan S, Ferrari G, Tomaras GD, Montefiori DC, Allen M, Chiu YL, Spearman P, Fuchs JD, Koblin BA, Blattner WA, Frey S, Keefer MC, Baden LR, Corey L. NIAID HIV Vaccine Trial Network. High-dose recombinant Canarypox vaccine expressing HIV-1 protein in seronegative human subjects. J Infect Dis. 2005. 7:1249–1259.
24. Letvin N. Progress and obstacles in the development of an AIDS vaccine. Nat Rev Immunol. 2006. 6:930–939.
XML Download